Skip to main content
Premium Trial:

Request an Annual Quote

Consortium Created to Identify Kinases for Drug Discovery

NEW YORK (GenomeWeb News) – A consortium comprising six industry players and academic partners has been created to identify kinases that could serve as drug targets.

The consortium consists of drug discovery firm SARomics Biostructures; medicinal chemistry company Prestwick Chemical; contract service organization ProQinase; the University of Turin in Italy; the Israel Structural Proteomics Center at the Weizmann Institute of Science; and the TechMedIll platform of the University of Strasbourg, France.

The EU 7th Framework Program "Research for the Benefit of SMEs" is providing €1.1 million ($1.4 million) to the consortium called the Translational Kinase Tumor Inhibitor Discovery Consortium, or TAKTIC.

"The merging of the highly complementary capabilities of the six partners within the TAKTIC Consortium enables an efficient and versatile kinase drug discovery platform that will target some challenging and medically important kinases," TAKTIC said in a statement.